Nervgen Pharma (NGEN) Research & Development (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Research & Development came in at $5.7 million in Q2 2026, up 191.57% year-over-year from $2.0 million in Q2 2025, and up 60.86% quarter-over-quarter from $3.5 million in Q1 2026.
Powered by 
Analysis
Nervgen Pharma (NGEN) Research & Development (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Research & Development for 2 consecutive years, with $5.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Research & Development rose 191.57% year-over-year to $5.7 million in Q2 2026; TTM through Jun 2026 was $13.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.0 million, down 13.64% from the prior year.
- Research & Development was $5.7 million for Q2 2026 at Nervgen Pharma, up from $3.5 million in the prior quarter.
- Over five years, Research & Development peaked at $5.7 million in Q2 2026 and troughed at $2.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Nervgen Pharma | 152.26 Mn | 152.26 Mn | - | 5.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.71 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Jun 30, 2025 | 1.96 Mn |
| Mar 31, 2025 | 2.19 Mn |